Search research articles
Contact Us
Filters
Showing results (151-160 of 221) with videos related to
Page
of 23
Sort By:
Plos One
|
May 10, 2024
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
Fanny Porte, Anna Granghaud, Jane Chang, et al.
Lancet (London, England)
|
December 25, 2007
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, et al.
Cancer Treatment Reviews
|
June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies
Bernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 9, 2020
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
Sylvie Negrier, Nathalie Rioux-Leclercq, Céline Ferlay, et al.
Lancet (London, England)
|
July 26, 2008
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J Motzer, Bernard Escudier, Stéphane Oudard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Brian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2018
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
Daniel J George, Jean-François Martini, Michael Staehler, et al.
Cancer
|
June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study
Brian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2018
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Daniel J George, Jean-Francois Martini, Michael Staehler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 7, 2026
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET
Sylvie Negrier, Loïc Mourey, Cécile Dalban, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 221) with videos related to
Sort By:
Page
of 23
Plos One
|
May 10, 2024
Cost-effectiveness of avelumab first-line maintenance therapy for adult patients with locally advanced or metastatic urothelial carcinoma in France
Fanny Porte, Anna Granghaud, Jane Chang, et al.
Lancet (London, England)
|
December 25, 2007
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, et al.
Cancer Treatment Reviews
|
June 22, 2011
Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies
Bernard Escudier, Susanne Osanto, Börje Ljungberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 9, 2020
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
Sylvie Negrier, Nathalie Rioux-Leclercq, Céline Ferlay, et al.
Lancet (London, England)
|
July 26, 2008
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert J Motzer, Bernard Escudier, Stéphane Oudard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2018
Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Brian I Rini, Bernard Escudier, Jean-Francois Martini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2018
Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
Daniel J George, Jean-François Martini, Michael Staehler, et al.
Cancer
|
June 14, 2012
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study
Brian Rini, Cezary Szczylik, Nizar M Tannir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2018
Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Daniel J George, Jean-Francois Martini, Michael Staehler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 7, 2026
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET
Sylvie Negrier, Loïc Mourey, Cécile Dalban, et al.
Page
of 23